Navigation Links
Unigene's Potent, Anorexigenic Peptide, UGP281, Demonstrates Dramatic Dose Dependent Reductions in Food Intake with Subsequent Significant Body Weight Reduction in Preclinical Studies
Date:5/22/2012

iencies, our ability to enter into new financing arrangements,  the ability of our products to gain market acceptance and increase market share, the uncertainty of results of animal and human testing, the risk of product liability and liability for human clinical trials, our dependence on patents and other proprietary rights and the risks associated with patent litigation, dependence on key management officials, the availability and cost of capital, the availability of qualified personnel, changes in, or the failure to comply with, governmental regulations, general economic and business conditions, our history of losses and ability to achieve profitability, litigation and other risk factors discussed in our Securities and Exchange Commission ("SEC") filings, including our annual report on Form 10-K and our quarterly reports on Form 10-Q. Words such as "anticipates," "expects," "intends," "plans," "predicts," "believes," "seeks," "estimates," "may," "will," "should," "would," "potential," "continue," and variations of these words (or negatives of these words) or similar expressions, are intended to identify forward-looking statements, but are not the exclusive means of identifying forward-looking statements. In addition, any statements that refer to expectations, projections, contingencies, goals, targets or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements and are not statements of historical fact. Except as required by applicable law, including the securities laws of the United States and the rules and regulations of the SEC, we are under no obligation to publicly update or revise any forward-looking statements after the date of this release.

Investor Contact:
Unigene Laboratories, Inc.
Jenene Thomas
VP, Investor Relations and Business Administration
973-265-1107
jthomas@unigene.com

<
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. TargeGen Affiliates Scheduled for Oral Presentation of Interim Clinical Trial Data at 2008 ASH Meeting in San Francisco for TG101348, a Potent, Selective, Oral JAK2 Inhibitor in Myeloproliferative Disease Patients
2. Micromet Demonstrates That the Antibodies in Commercial Products Herceptin, Erbitux, Vectibix and Xolair Can Be Converted Into Highly Potent, T Cell- Engaging BiTE Antibodies
3. Ceregene Parkinsons Disease Study Demonstrates Long-term Neurturin Expression and Enhanced Dopamine Activity 4 Years Following Delivery of CERE-120 (AAV2-neurturin)
4. AXIOS™ Stent and Delivery System Study Demonstrates Successful Treatment of Pancreatic Pseudocysts and Acute Cholecystitis
5. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
6. OncoSec ElectroChemotherapy Demonstrates Potential as Alternative to Surgery for Treating Head and Neck Cancer
7. Soligenix Demonstrates Positive Proof of Concept with its Proprietary Vaccine Thermostabilization Technology
8. Boston Scientific Epic™ Stent Demonstrates Positive Clinical Outcomes in Orion Trial
9. 10-Year Study Demonstrates IRIDEX MicroPulse™ Laser Therapy Safe, Effective for Patients with Diabetic Macular Edema
10. The New England Journal of Medicine Publishes Study Showing LigoCytes Norovirus Vaccine Demonstrates Protection Against Illness
11. Fujifilm Demonstrates the Latest Advancements of Synapse® PACS at RSNA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... -- (Booth #7309, North Hall) — Dicom Systems ... Interface WebBridge, at the 100th annual RSNA Meeting held ... Chicago, Illinois . Photo ... medical facilities of any size, WebBridge allows any native ... data (e.g. JPEG, TFF, PDF, TXT, etc.) to DCMSYS ...
(Date:11/28/2014)... Nov. 28, 2014 Alimera Sciences, Inc. ... company that specializes in the research, development and ... a Securities Purchase Agreement with Deerfield Management and ... Alimera will issue shares of preferred stock to ... $50.0 million upon the satisfaction of certain closing ...
(Date:11/28/2014)... Chinese magnesium alloy maker DongGuan Eontec Co., ... alloy bone fixation screw has received Chinese regulatory inspection ... instrument and that the company acknowledges receipt of the ... Science and Technology Daily journalists Wang Xiangming and ... founder, Professor Li Yangde , has been a ...
Breaking Medicine Technology:Dicom Systems Announces WebBridge Interface at RSNA 2014 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 2Alimera Sciences Announces Agreement with Deerfield Management for $50.0 Million Financing 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 2Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 3Chinese magnesium alloy manufacturer Eontec expects to have its medical magnesium alloy available for clinical trial in 2015 4
(Date:11/28/2014)... 28, 2014 Novatus, a leading ... Release v5.1 which provides customers with greater reporting ... , “As we continue to evolve and ... more functionality and improved performance in response to ... for Novatus. “With the enhancements that we have ...
(Date:11/28/2014)... Gables, Florida (PRWEB) November 28, 2014 ... Thanksgiving, Turbana and Sendik’s will present Feeding America Eastern ... with Sendik’s Food Market to donate a portion of ... participated in Sendik’s promotion, “7 Days, 7 Ways to ... throughout fall, Fyffes pineapples were two for $4 and ...
(Date:11/28/2014)... New York (PRWEB) November 28, 2014 ... continuing to move forward in New Jersey’s Bergen ... in a consolidated litigation established there is quickly ... List updated on November 18th shows 1,293 lawsuits ... created for lawsuits that allege complications resulting from ...
(Date:11/28/2014)... 2014 Dr. Andrew Campbell, one of ... the expansion of Quintessa Aesthetic Center into a third ... at W307 N1497 Golf Road in Suite 200 and ... Campbell, the new Delafield location will offer a variety ... including: Botox, filler injectables , micro laser peels, ...
(Date:11/28/2014)... 28, 2014 Dr. Diane Walder, one of ... new treatment to her practice called Ultrashape that is designed ... three inches in just six weeks. Ultrashape has been praised ... superior in results when compared to other types of external ... treat it,” said Dr. Walder. , According to Dr. ...
Breaking Medicine News(10 mins):Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 2Health News:Turbana Partners With Sendik's Food Market to Donate $11,500 to Local Hunger-Relief Non-Profit 3Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 2Health News:Nearly 1,300 Mirena Lawsuits Now Filed in Consolidated New Jersey Litigation, Bernstein Liebhard LLP Reports 3Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 2Health News:Dr. Diane Walder Introduces New Fat Reduction Treatment Called Ultrashape 3
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... Loyola University Health System study includes some unexpected ... Contrary to expectations, patients who died from their ... than patients who survived., "Perhaps a better understanding ... for therapies that further improve outcomes in burn ...
... CAWhen cells find themselves in a tight spot, the ... cells time to repair the damage, or if all ... to other stress-induced genes, which dispense with the regular ... factor that also helps with the editing of transcripts, ...
... children and adolescents. In the current issue of ... 173-79), Susanne Walitza and her colleagues point out that ... course of the disease. Compulsive washing, the most ... in up to 87% of all patients; other common ...
... The United States should pay close attention to how the ... worth using factors that go beyond clinical and cost effectiveness, ... Bioethics. In a commentary to appear in the April ... , the bioethicists detail and discuss a new, "value-based pricing" ...
... establishes a unique system to perform in vivo ... networks that regulate hepatocyte proliferation during chronic liver ... that stable knockdown of the candidate gene by ... of mouse hepatocytes and also increase the regenerative ...
Cached Medicine News:Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 2Health News:'SKIP'-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Surprising finding from smoke inhalation study 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 2Health News:‘SKIP’-ing splicing forces tumor cells to undergo programmed cell death 3Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 2Health News:Placing value, price on new drugs: The challenge facing new UK policy, say Hopkins bioethicists 3
Direct gonioscopy lens with magnification. The lens rests on the scleral flange creating a corneal vault and leaving the anterior chamber angle undisturbed. Three sizes available....
West lachrymal cannula, blunt tip with inner side opening, gently curved shaft....
Lachrymal cannula, straight....
Solo-care is a multi-purpose solution for cleaning, rinsing, disinfection and storing soft contact lenses....
Medicine Products: